However, GDF15 testing is currently predominantly restricted to research environments; thus, further translational and implementation research is required to evaluate its practicality, cost-effectiveness, and integration into standard clinical workflows for patients with PAD. The gene discussed is GDF15; the disease is peripheral arterial disease.